Biopharma M&A in 2024 — Five Considerations for Deal Execution
Vantage Partners
JANUARY 19, 2024
It’s no great secret that M&A activity in bipoharma has been on the rise over the past 12 months. Analysis from EY found that life sciences M&A spend was up 34% last year relative to 2022, despite a reduction in deal volume. Activity among Big Pharmas in 2023 ( Merck + Prometheus ; Pfizer + Seagen ) dominated headlines, and major deal announcements around this year's JPM Healthcare conference (including Merck's acquisition of Harpoon Therapeutics , J&J's acquisition of Ambrx , and GS
Let's personalize your content